Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash & Equivalents (2020 - 2021)

Design Therapeutics' Cash & Equivalents history spans 2 years, with the latest figure at $357.7 million for Q3 2021.

  • For Q3 2021, Cash & Equivalents changed N/A year-over-year to $357.7 million; the TTM value through Sep 2021 reached $357.7 million, changed N/A, while the annual FY2020 figure was $2.4 million, N/A changed from the prior year.
  • Cash & Equivalents for Q3 2021 was $357.7 million at Design Therapeutics, down from $370.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $400.7 million in Q1 2021 and bottomed at $2.4 million in Q4 2020.